Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors
- 8 May 2024
- journal article
- research article
- Published by Elsevier in Cytotherapy
- Vol. 26 (9) , 1026-1032
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- Stand Up To Cancer
- NHLBI
- National Institutes of Health
- CPRIT
This publication has 34 references indexed in Scilit:
- Prolonged Cytopenias after Commercial CAR T-Cell Therapy with Tisagenlecleucel and Axicabtagene Ciloleucel for Relapsed and Refractory DLBCLTransplantation and Cellular Therapy, 2023
- Patterns of Leukocyte Recovery after CD19 Chimeric Antigen Receptor T-Cell Therapy in a Real-World SettingTransplantation and Cellular Therapy, 2023
- Risk Factors and Outcomes for Patients with Persistent Cytopenia Following Administration of CD19 CAR-T Cell Therapy in B Cell LymphomaTransplantation and Cellular Therapy, 2023
- Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapyBone Marrow Transplantation, 2022
- Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphomaCancer Medicine, 2022
- Managing the toxicities of CAR T‐cell therapyHematological Oncology, 2019
- Early and late hematologic toxicity following CD19 CAR-T cellsBone Marrow Transplantation, 2019
- In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin’s LymphomasMolecular Therapy, 2018
- CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with NeuroblastomaMolecular Therapy, 2017
- Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapyCancer, 2005